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Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of 
cancer-related death in men. PCa is a highly heritable disease and genetic factors explain 58 % of 
the risk. Studies on PCa have led to identification of germline mutations associated with PCa, and 
the G84E mutation in HOXB13 is one of these identified mutations. This germline mutation was 
identified almost a decade ago in 2012, however, its function and mechanism in PCa progression 
remain elusive.  
 
Prime editing is a novel genome editing method where new genetic information is added into a 
specific DNA site with the prime editor (PE) containing catalytically impaired Cas9 endonuclease 
fused to reverse transcriptase (RT) and green fluorescent protein (GFP). An additional prime 
editing guide RNA (pegRNA) contains the template with the desired edit and targets the PE to 
the specific site in the genome. 
 
The aim of the thesis was to generate the G84E mutation in HOXB13 with prime editing. Three 
different pegRNAs with different lengths of primer binding sites (PBS) were generated to see 
which is the most efficient. Single guide RNA (sgRNA) was used to nick the non-edited strand 
which favors the DNA repair of the non-edited strand forcing the cells to use the newly PE edited 
strand as a template. Protein lysates of PCa cell lines were prepared and analyzed with Western 
blot to see if they express HOXB13. LNCaP cells expressing HOXB13 were transfected with 
plasmid constructs and GFP-positive cells were sorted. Gene editing efficiency was measured 
with droplet digital PCR (ddPCR). pegRNA with a PBS of 16 nucleotides (nt) worked with 
approximately 10 % efficiency, but the efficiency of pegRNA with PBS of 13 nt remains unclear. 
PBS of 10 nt did not work at all suggesting that it is too short for proper binding to the target 
DNA. In conclusion, pegRNA with PBS16 can be used to generate HOXB13G84E cellular model 
for further studies of the mutation to understand its role in PCa progression. 
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The development of cancer is a complex, multi-step process with different factors 
contributing to the progression. Deregulation of cellular genetics is one of the eight 
Hallmarks of cancer (Hanahan & Weinberg, 2011). Inactivating loss of function 
mutations in tumour suppressor genes (TSGs), which normally control cell cycle and 
promote apoptosis, and activating gain of function mutations in oncogenes, which 
promote cell cycle progression and inhibit apoptosis, are typically contributing to 
carcinogenesis (Strachan & Read, 2019). There are several factors increasing cancer risk, 
and genetic factors can be considered as one of these.  
Prostate cancer (PCa) is the second most common cancer in men worldwide, and it is a 
highly heritable disease (Hjelmborg et al., 2014; Rawla, 2019). PCa research and has led 
to identification of several genetic factors contributing to PCa progression and these have 
benefited PCa patients and led to increased life expectancy due to improved screening. 
Despite the improvements, PCa still remains one of the most common causes of cancer-
related deaths among men (International Agency for Research on Cancer (IARC), World 
Health Organization (WHO)).  
Studying PCa genetics is crucial for developing treatments and for identification of new 
screening targets. Therefore, cellular models of the mutations predisposing to cancer are 
required for studying the function of these mutations in the progression of the disease. 
Different genetic tools have been used over the past decades with Clustered regularly 
interspaced short palindromic repeats/CRISPR-associated protein 9 endonuclease 
(CRISPR-Cas9) being among the most commonly used ones now, but development of 
new precise tools is required for better editing efficiencies and for minimizing undesired 
off-target effects. The aim of this thesis was to make tools for generating the G84E 
mutation in HOXB13 with prime editing. These tools can later be used to generate cellular 






1. Review of the Literature 
1.1 Prostate cancer 
1.1.1 Epidemiology 
PCa is the most common cancer diagnosed among men in Finland with more than 5 000 
cases diagnosed per year (The Finnish Cancer Registry, 2018 report). It is the second 
leading cause of cancer-related death in men with approximately 900 deaths per year even 
though the mortality rate is relatively low with five-year survival rate of 93 % (The 
Finnish Cancer Registry, 2018 report). Worldwide, PCa is the second most common 
cancer and the fifth leading cause of cancer-related death in men (IARC, WHO). 
1.1.2 Risk factors 
PCa risk increases with age and cases with early onset tend to be more aggressive than 
cases with late onset (Grönberg et al. 1999). PCa prevalence varies among groups with 
different ethnicity and the rates are the highest in African Americans. This is explained 
by both biological and socioeconomic factors: prostate specific antigen (PSA) levels were 
higher in African American compared to others, and they might not receive as high-
quality healthcare and are less likely to undergo screening. (Kolonel et al., 2004; 
Vijayakumar et al., 1998.) 
Family history is also one of the known risk factors of PCa. Men with a first-degree 
relative with PCa diagnosis at age <60 have over 2-fold risk of developing PCa. Familial 
PCa has also been associated with early onset and more aggressive cancer. (Chen et al. 
2008.) 
Migration studies have indicated that PCa risk increased among Asians who had moved 
to the United States (Lee et al., 2007). This suggests that dietary factors have an influence 
on PCa risk, because the Western countries tend to have a diet higher in fat and red meat. 
However, only a few dietary factors have been established so far to increase PCa risk. 
Dairy, red meat and saturated fats have been associated with increased risk (Aune et al., 
2015; Chan et al., 2005). Other lifestyle factors that increase the PCa risk are low physical 





Hanahan and Weinberg described the Hallmarks of Cancer theory (Figure 1) consisting 
of properties needed for a normal cell to transform into a cancerous cell. Genetic 
alterations is one of these hallmarks. Other hallmarks are resisting cell death, deregulating 
cellular energetics, sustaining proliferative signaling, evading growth suppressors, 
avoiding immune destruction, enabling replicative immortality, tumour-promoting 
inflammation, activating invasion and metastasis, and inducing angiogenesis. (Hanahan 
& Weinberg, 2011.)  
 
Figure 1 The hallmarks of cancer. Different types of cancers have individual properties, and 
they develop through different mutations or alterations in epigenetic modifications. However, 
tumours possess similar properties that either can cause the development of cancer or are a 
consequence of cancer. These common properties are called hallmarks of cancer. Modified from 
Hanahan & Weinberg (2011). 
There are several types of genomic alterations that can affect entire chromosomes or 
distinct genes (Figure 2). Chromosomal rearrangements are insertions, deletions, 
inversions, duplications and translocations whereas alterations in DNA sequence are 
deletions, insertions and substitutions. These genetic alterations can be somatic or 





Figure 2 Different types of genetic alterations. Genetic alterations can affect entire 
chromosomes, individual genes and other parts of DNA sequences. Deletion, duplication, 
insertion, translocation and inversion are types of chromosomal rearrangements, whereas 
substitution, deletion and insertion are types of alterations in DNA sequence. 
Genetic alterations enable the acquisition of many of the hallmarks described previously. 
Mutations may give cells a growth advantage or then increase the mutation rate by 
destabilizing the genome. Cancers develop in stages by accumulating random mutations 
and by generating a diverse heterogeneous cell population until ultimately, one cell 
acquires the capability to form a tumour. The mutations which are responsible for 
tumorigenesis are called “driver mutations” and the background mutations are called 
“passenger mutations”. The genes that gain these driver mutations in oncogenesis are 
divided into TSGs and oncogenes. (Strachan & Read, 2019.) 
Oncogenes are mutated proto-oncogenes with a natural function of promoting 
proliferation. In benign cells, proto-oncogenes are regulated and are activated in response 
to specific signals. However, if a gain-of-function mutation occurs, control over 
regulation is lost and this will lead to uncontrollable cell growth and proliferation. These 
activating gain-of-function mutations can be caused by point mutations or by 
amplification of an oncogene. (Strachan & Read, 2019.) Translocations can also lead to 
formation of a novel chimeric gene which can be more active than the original gene. The 
Philadelphia chromosome is the most well-known example of this situation. The 
Philadelphia chromosome is a result from translocation of chromosomes 22 and 9. 
Breakpoint cluster region (BCR) gene from chromosome 22 and ABL, a proto-oncogene 
encoding a tyrosine kinase from chromosome 9, are brought together by a translocation 




TSGs are the second major class of genes mutated in cancers. Their normal function is to 
control cells by suppressing cell division, maintaining genomic integrity and inducing 
apoptosis. Unlike oncogenes, TSGs promote cancer progression by acquiring loss-of-function 
mutations that inactivate them. Most TSGs require inactivating mutations in both alleles of 
the gene to lose their proper function (Figure 3). (Strachan & Read, 2019; Weinberg, 1991.) 
 
Epigenetic modifications are reversible, and they do not alter the DNA sequence. The 
most common modifications are DNA methylation and post-translational modifications 
in histone proteins (Figure 4). Gene expression can be regulated by these epigenetic 
modifications and therefore, they can promote cancer progression by silencing TSGs or 
by upregulating oncogenes. (Sharma et al., 2010; Albany et al., 2011) 
 
Figure 4 Epigenetic modifications. Epigenetic modifications are heritable changes in the 
expression of genes, which do not involve alterations in the DNA sequence. Epigenetic 
modifications involve changes in the chromatin structure, posttranslational histone 
modifications, DNA methylation and noncoding RNAs. 
Figure 3 Knudson’s two-hit hypothesis. For a tumour suppressor gene (TSG) to promote 
carcinogenesis, usually two hits are required for both alleles of the gene in order for a gene to 




PCa is a highly heritable disease with genetic factors explaining 58 % of the risk 
(Hjelmborg et al., 2014). Germline mutations, which are mutations located in the germ 
cells and are inherited, have been associated with more aggressive disease and poorer 
outcome (Pritchard et al., 2016). Breast cancer genes BRCA1 and BRCA2 are both TSGs 
participating in the DNA repair process, and loss of their proper function leads to a defect 
in the repair process of double-strand breaks (DSB) called homology directed repair 
(HDR) process. Mutations in BRCA1 and BRCA2 have been associated with PCa 
susceptibility. The risk of PCa by the age of 80 years varies from 19 % to 61 % for mutated 
BRCA2 carriers and from 7 % to 26 % for BRCA1 (Lecarpentier et al., 2017). Germline 
mutations in BRCA2 are also enriched in metastatic PCa cases. CHEK2 (checkpoint 
kinase 2), which encodes a checkpoint kinase, MSH2 (MutS homolog 2), which encodes 
a DNA mismatch repair protein, ATM (ATM serine/threonine kinase), which encodes a 
serine/threonine protein kinase, RNASEL (ribonuclease L), which encodes ribonuclease 
L inducing apoptosis, and HOXB13 (homeobox b13), which encodes transcription factor 
needed in embryonic development, have also been associated with PCa susceptibility 
(Pritchard et al., 2016). Mutations in BRCA2 do not appear to have as important role in 
the Finnish population (Ikonen et al., 2003). The most relevant PCa susceptibility genes 
in Finland are RNASEL, CHEK2 and HOXB13, and the germline variant G84E in 
HOXB13 has the strongest impact on PCa susceptibility (Laitinen et al., 2013). 
Somatic mutations arise spontaneously and can be induced by different environmental 
factors such as chemicals or radiation. Somatic mutations driving PCa progression usually 
occur in genes participating in androgen signaling pathways and DNA repair pathways, 
however, mutations in epigenetic regulators and spliceosome pathway have also been 
identified in PCa cases (Armenia et al., 2018). Somatic mutations found in metastatic 
castration resistant prostate cancer (mCRPC) cases frequently occur in AR (androgen 
receptor), TP53 (tumour protein 53), PTEN (phosphatase and tensin homolog), APC 
(adenomatous polyposis coli) and BRCA2 (Robinson et al., 2015).  
1.1.4 Prostate anatomy and tumorigenesis 
The human prostate is located below the urinary bladder and it surrounds the urethra. The 
prostate consists of three different histological zones: peripheral zone, transition zone and 
central zone (Figure 5). The peripheral zone is the major component of prostate, 
constituting about 70 % of tissue, and it is the origin site of majority of prostate cancers. 




where hyperplasia develops. The central zone is not a cancer origin site, but it can be 
secondarily involved in the disease progression. (McNeal, 1981; Ittmann, 2018.) 
 
Figure 5 Histological zones of the prostate. The prostate is divided into three zones: peripheral, 
transition and central zone. The peripheal zone is the major component and comprises 
approximately 70 % of the tissue, whereas the transition zone accounts for approximately 5 % of 
the prostate. Adapted from Hedayat & Lapraz (2019). 
The prostate glands consist of three different epithelial cell types: basal, luminal and 
neuroendocrine cells. The cell types are defined by their gene expression profiles, surface 
antigens, shape and position. Basal epithelial cells express cytokeratin 5 and p63, which 
is a transcription factor, and luminal epithelial cells express cytokeratin 8 and kallikrein 
3 (KLK3), a secretory protein regulated by androgens. (Henry et al., 2018). The luminal 
cells have a secretory function and are responsible for producing mucus, which forms 
most of the semen. Neuroendocrine cells are rarer, and they express endocrine markers, 
but do not possess androgen receptors such as basal and luminal cells. (Shen & Abate-
Shen, 2010.) 
The development of PCa is a multi-step process. Cells start to proliferate in an 
uncontrolled manner inside the prostate gland and prostatic intraepithelial neoplasia (PIN) 
is formed. In this stage, the basement membrane remains uninvaded. More changes in the 
gene expression pattern occurs and the next step is the formation of low-grade carcinoma 
where the basement membrane is invaded by rapidly dividing luminal cells. The next step 
is high-grade carcinoma and ultimately, metastasis. (Shen & Abate-Shen, 2010.) 




processes in initiation of PCa are inflammation, DNA damage and telomere shortening, 
and as it progresses, cellular senescence and re-activation of developmental signaling 
pathways occur in cancer cells. At the stage of metastasis, signaling processes allowing 
epithelial-mesenchymal transition (EMT) are activated, and this is the stage where the 
cancer usually becomes castration-resistant. During the whole process, different 
oncogenes are overexpressed and TSGs are inactivated or down-regulated. (Shen & 
Abate-Shen 2010.)  
1.1.5 Diagnostics 
Early detection of PCa is one of the key aspects to increase survival rate, but since PCa 
does not always cause any symptoms or then the symptoms can be similar with other 
urinary problems, it may lead to late detection of the disease. Measuring the PSA levels 
in blood is currently the most sensitive marker available for screening PCa. PSA is a 
serine protease encoded by the KLK3 gene and secreted by prostate epithelial cells. 
(Schröder, 2010.) The normal PSA serum concentration for healthy men is 0 – 2,5 ng/ml, 
and the concentration is elevated in men suffering from PCa. PSA-level in blood is 
proportional to both the clinical stage of PCa and to the volume of the tumour within the 
prostate. (Stamey et al. 1987.) PSA-testing is also used in monitoring the treatment 
responses because it indicates the effectiveness of the treatment. Despite the fact that 
PSA-testing is widely used now, it causes controversy since the downside of it is 
overdiagnosis due to poor specificity, which results in aggressive treatments of cancer 
cases that would not be lethal. (Sharma et al., 2017) 
The gold standard for PCa diagnosis is prostate biopsy. Magnetic resonance imaging 
(MRI) and ultrasound are used to target the biopsy to the cancer site. The biopsy samples 
are histologically evaluated with Gleason scale, where cancer grade is evaluated with 
numbers between three to five (Gleason, 1966). The Gleason score combines two 
numbers, the most common and the second most common Gleason grades, and it can vary 
between six and ten, and the higher the score is, the more aggressive the cancer is (Sharma 
et al., 2017). 
PSA is currently the only biomarker used in PCa detection and disease monitoring, 
however systematic PSA-testing is recommended only for men with family history of 
PCa and who are therefore at a high risk of developing PCa. The main benefits of PCa-
screening are the reduction of unnecessary and invasive biopsies and digital rectal 




limitations due to its poor specificity, and this is why finding new cancer-specific 
biomarkers have been a great interest of researchers. (Sharma et al., 2017)  
1.1.6 Treatment 
In the case of localized PCa, monitoring, surgery and radiation are the primary treatment 
methods. In radical prostatectomy, the prostate and its surrounding tissues and seminal 
vesicles are removed. Prostatectomy is usually recommended for intermediate- and high-
risk patients whereas radiation therapy for those with shorter life expectancy. Other 
treatments for local PCa cases are laser ablation, cryotherapy and high-intensity-focused 
ultrasound. (Litwin & Tan, 2017.) 
In the case of metastatic PCa, patients usually receive androgen deprivation therapy 
(ADT) either by surgical or chemical castration to decrease the amount of circulating 
testosterone. In most of the cases where patient receives ADT, a resistance is developed, 
and this results in cancer progression towards castration-resistant prostate cancer (CRPC). 
(Nevedomskaya et al., 2018.) 
Huggins and Hodges discovered the central role of androgen signaling in PCa in 1941, 
and it is now clear that the majority of prostate tumours express androgen receptor (AR) 
(Dai et al., 2017). The development of CRPC is usually result of restored androgen 
signaling and it is treated with AR-targeted drugs to achieve androgen deprivation with 
antagonists of the AR ligands, or by reducing androgen synthesis. Antagonists of 
dihydrotestosterone (DHT) are used for blocking the AR function, and androgen synthesis 
is usually reduced with Cytochrome P450 Family 17 Subfamily A Member 1 (CYP17A1) 
lyase inhibitors. If the disease continues to progress despite the medication, cytostatic 
drugs and second-generation AR antagonists are given to the patients. (Dai et al., 2017; 
Nevedomskaya et al., 2018.) 
mCRPC is treated with additional therapies which include taxanes, radium-223 and 
sipuleucel-T. Radium-223 is used for patients with bone metastasis in combination with 
other drugs. (Nevedomskaya et al., 2018.) 
Docotaxel and cabazitaxel are chemotherapeutic drugs approved by the U.S. Food and 
Drug Administration (FDA) in 2004 and 2010, respectively. They are used in the 
treatment of mCRPC and their mechanism of action is preventing mitotic cell division by 
inhibiting tubulin depolymerization thus resulting in cell death. Cabazitaxel is a second-




mCRPC treatment, but second-generation antiandrogens are now preferred since taxanes 
have more side effects. (Nevedomskaya et al., 2018.) 
Sipuleucel-T is used for autologous cellular immunotherapy and it was approved in 2010. 
In this immunotherapy, peripheral blood mononuclear cells are obtained from the patient 
and cultured ex vivo in the presence of prostatic acid phosphatase (PAP) fused to 
granulocyte-macrophage colony stimulating factor (GM-CSF) to achieve an immune 
response. PAP is almost exclusively expressed by prostate cells and therefore it is an 
excellent target. This activated sipuleucel-T product is then returned back into the patient 
intravenously. Clinical benefits and only few mild side effects have been reported, but 
the costs of this therapy are high, and it is also laborious and therefore its usage has been 
limited. (Nevedomskaya et al., 2018.) 
Novel and effective drugs are still needed for the treatment of PCa. With personalized 
precision medicine paving the way, best treatment strategies for individuals are 
determined. The costs however are higher, and it is more laborious to perform individual 
treatments compared to conventional therapies. Identification of novel biomarkers also is 
one of the major aspects in the field of PCa diagnostics and treatment since they would 
provide aid for selecting optimal drug combinations for PCa patients by helping to predict 
the drug response and the disease progression. (Nevedomskaya et al., 2018; Rice et al., 
2019.) 
 
1.2 HOXB13 and PCa 
1.2.1 The homeobox gene family 
HOX genes are a highly conserved subgroup of the homeobox superfamily. HOX genes 
encode proteins that are transcription factors critical for normal embryonic development 
and master regulators which can either activate or repress other genes. In 1921, Morgan 
and Bridges were the first ones to propose existence of HOX genes. They observed 
changes in body structure development in Drosophila melanogaster mutants and 
therefore suggested that there are genes responsible for correct spatial body development 
in fruit flies. Despite the findings of Morgan and Bridges, HOX genes and their protein 
structure were confirmed in humans nearly 70 years later in 1990 (Nourse et al., 1990; 




The common characteristic of HOX genes is the 120 base pair (bp) DNA sequence, 
homeobox sequence, encoding the homeodomain. Homeodomain is the DNA-binding 
domain, and it is located in exon 2. (Bhatlekar et al., 2014.) HOX genes are located within 
clusters in vertebrates, and the amount of these clusters vary according to the anatomic 
complexity of the organism. There are four clusters in four different chromosomes and 
39 identified HOX genes in humans (Figure 6). (Shah & Sukumar, 2010.)  
 
Figure 6 Classification of the 39 identified HOX genes in humans. There are 39 identified HOX 
genes located in four different clusters and chromosomes in humans. Cluster A is in chromosome 
7 and has 11 HOXA genes, cluster B is in chromosome 17 and has 10 HOXB genes, cluster C is 
in chromosome 12 and has 9 HOXC genes, and cluster D is in chromosome 2 and has 9 HOXD 
genes. The genes illustrated in red and orange (HOXA-D 1-6) are expressed in the most anterior 
parts of the human body such as face and neck, those illustrated in green (HOXA-D 7-8) in 
abdomen, and those illustrated in blue (HOXA-D 9-13) are expressed in the posterior parts of the 
body such as limbs and genitals. Adapted from Features of the animal kingdom: Figure 4, 
OpenStax College, Biology. 
The nomenclature of HOX genes is based on the cluster where it is located. The four 
clusters are A for chromosome 7, B for chromosome 17, C for chromosome 12 and D for 
chromosome 2. The genes are numbered between 1 - 13 according to their position, 
starting from the ends where genes expressed in anterior parts of the body are located. 
(Scott, 1992.)  
There are three basic precepts in what mechanisms the HOX genes control and are 




position of a gene 3’ to 5’ within a cluster corresponds to its expression along the anterior-
posterior (A-P) axis. Genes located in 3’ are generally expressed in anterior tissue 
whereas 5` genes in the posterior tissues. Second is the posterior prevalence, meaning that 
the HOX genes positioned in 5’ cluster have a more dominant phenotype. Third is the 
temporal collinearity, meaning that the HOX genes are expressed in order corresponding 
to their position (3’ to 5’). (Shah & Sukumar 2010.) 
HOX genes have been linked to various cancers because their protein products promote 
carcinogenesis by activating oncogenes or by suppressing TSGs. This indicates that both 
up- and downregulation of HOX genes can be critical for cancer progression. (Bhatlekar 
et al., 2014.) 
1.2.2 HOX genes in carcinogenesis 
Many of the molecular pathways that are associated with normal growth and development 
are also associated with carcinogenesis. The first suggestions of HOX genes and their role 
in carcinogenesis were that they promote cancer progression by being upregulated in 
cancer cells, but now it is known that the actual mechanisms are far more complex. The 
aberrant expression of HOX genes in cancer can be classified into three different 
mechanisms. The first is that the HOX genes can be re-expressed in tumour cells 
originated from embryonic cells where the gene is normally expressed during 
development. The second is that the HOX genes can also be expressed in tumour cells 
originated from cells in which the HOX gene is not normally expressed, but these cases 
seem to be rarer compared to the previous mechanism. Third is that HOX genes are 
downregulated in those tumour cells that originate from a tissue where a HOX gene is 
expressed even in the differentiated state. (Abate-Shen, 2002.) In cancerous tissue, 
changes in gene expression patterns, especially increased expression levels, usually occur 
with those HOX genes that have oncogenic functions, whereas HOX genes that have 
tumour suppressing properties are usually silenced. (Shah & Sukumar, 2010.)  
Epigenetic regulation of HOX genes have been shown in the case of primary squamous 
cell carcinoma of the lung. Rauch et al. reported that methylation analysis of HOXA genes 
(HOXA7 and HOXA9) revealed highly methylated CpG islands within the gene promoters 
in stage 1 tumours. Cases where upregulation of HOX genes in lung carcinomas occur 
have also been reported. Abe et al. showed that the expression levels of HOXA1, A5, A10 
and HOXC6 were higher in squamous cell carcinoma tissues when compared with normal 




of lung carcinomas because they compared HOX gene expressions in squamous cell 
carcinoma and adenocarcinoma tissues, and the results showed elevated expression of 
HOXA1, HOXD9, D10 and D11 in squamous cell carcinoma.  
Overexpression, downregulation and epigenetic silencing of HOX genes have also been 
reported in breast cancer. Wu et al. demonstrated that HOXB7 overexpression occurs in 
primary breast tumours and bone metastases, and it was shown to induce EMT in 
epithelial cells. HOXB13 overexpression has also been reported in breast cancer tissue 
compared to normal counterpart (Cantile et al., 2003). HOXA10 has been suggested to 
regulate p53 expression. Its downregulation results in downregulation of p53, a tumour 
suppressor protein, in estrogen receptor (ER) -positive tumours, implicating that 
downregulation of HOXA10 promotes cancer progression (Chu et al. 2004). As well as in 
the case of lung cancer, epigenetic silencing of HOX genes have been shown to be present 
in breast cancer cases also. Reisman et al. suggested that methylation of HOXA5 promoter 
would lead to downregulation of the gene expression and ultimately to loss of p53 
expression in breast cancer. 
Overexpression of HOXA9 has been associated with acute myeloid leukemia (AML) 
(Silverman et al., 2002; Faber et al., 2009). The exact mechanism how HOXA9 drives 
the proliferation of leukemia cells is not fully known. However, HOXA9 overexpression 
seems to upregulate insulin-like growth factor 1 receptor (IGF1R) in a B-lineage acute 
lymphoblastic leukemia cell line, which would indicate that the proliferation is a result 
from an autocrine cause (Whelan et al., 2008). HOXA9 can also promote AML by forming 
chimeric fusions resulting in upregulation of genes needed for cell proliferation like 
murine ectopic integration site 1 (MEIS1), a binding partner of HOXA9 (De Braekeleer 
et al., 2014). 
Elevated expression of HOXC genes has been reported in cervical cancer progression, 
and HOXC10 seems to take part in the progression of a high grade squamous 
intraepithelial lesion into invasive carcinoma by increasing the motility and invasiveness 
of cancerous epithelial cells (Zhai et al., 2007). Other HOX genes have also been 
associated with cancer progression in normal cervical cells (Hung et al., 2005). The 
mechanism how HOX genes promote the progression of invasive carcinoma is not known 
and more research would be needed. 
Several studies have implicated the role of HOX genes in ovarian carcinomas (Cheng et 




A9, HOXB2, B5, B6, B7 and HOXD1, and downregulation of HOXC6 was observed in 
microarray gene expression analysis where non-malignant and malignant ovarian tissues 
were analyzed (Bahrani-Mostafavi et al., 2008). Similar results indicating overexpression 
of HOX genes in ovarian cancer were obtained from a study where real-time quantitative 
PCR (RT-qPCR) assay was performed to create an expression profile of HOX genes using 
ovarian cancer cells and ovarian derived materials (Yamashita et al. 2006). Results from 
a study performed by Yamashita et al. revealed overexpression of 14 different HOX genes 
in the A and B clusters, and two genes in the C and D clusters. From these 16 genes, 
HOXB7, HOXA13 and HOXB13 were overexpressed almost exclusively in cancer cells 
and tissues, but only rarely or none in control cells and tissues.  
Aberrant expression of HOX genes in the prostate has been suggested to result in loss of 
differentiation and tumorigenesis. Waltregny et al. showed that HOXC8 is overexpressed 
in prostate adenocarcinoma and the levels correlate with loss of differentiation. HOXC4, 
C5 and C6 overexpression in malignant prostate cell lines and lymph node metastases has 
also been confirmed with RT-qPCR (Miller et al., 2003). HOXB13 is needed in the normal 
development of the human prostate, and its aberrant expression is associated with 
tumorigenesis (Jung, Kim, Zhang et al., 2004; Jung, Kim, Lee et al., 2004). However, the 
biological function of the gene in normal prostate development and PCa progression 
remains elusive. 
These findings indicate the numerous roles of HOX genes in cancer progression. Even 
though scientists have long been aware of HOX genes and their importance in normal 
embryonic development and in tumorigenesis, their complex mechanisms remain unclear. 
This indicates the importance of studying these genes in both normal and cancer tissue. 
Understanding downstream targets and regulators of HOX genes would help to 
understand their mechanism of action in normal development, and once their normal 
function is understood, their mechanisms in cancer progression can be elucidated.  
1.2.3 HOXB13 and its role in cancer progression 
HOXB13 is located in chromosome 17q21.32 and it consists of two exons (Figure 7). 
Since it is located at the 5’ end of the HOXB cluster and is one of the posterior HOX 
genes, it is expressed in the most posterior systems of the human body, and the 
reproductive tract is one of those. In normal conditions, HOXB13 expression is restricted 
to the prostate and colon tissue, however, aberrant expression is associated to different 




expression of HOXB13 has been reported in melanoma, colon and renal cancers (Brechka 
et al., 2017).  
 
Figure 7 Illustration of HOXB13 gene. The gene consists of two exons. Exon 1 is positioned at 
157 – 757 base pairs (bp) and contains two MEIS interaction domains. Exon 2 is positioned at 
1707 – 1960 bp and contains the DNA-binding homeobox domain. HOXB13 transcript is 3987 
bp long and the protein is 284 amino acids long. The germline mutation G84E is located in the 
exon 1 at the first MEIS interaction domain at position 84 of the protein sequence (NP_006352.2, 
ProtID Q92826). UTR=untranslated region, CDS=codine sequence, MEIS=murine ectopic 
integration site. Adapted from Brechka et al. (2017). 
Unlike HOXA13 and HOXC13 that are expressed mostly during development in murine 
prostate, HOXB13 is expressed into adulthood in multiple species (Brechka et al., 2017). 
Because HOXB13 is highly expressed into adulthood and it is the most differentially 
expressed of the HOX proteins when compared between lobes of the rodent prostate, it is 
suggested that it could have more important function in determining prostatic identity and 
maintaining organ homeostasis (Huang et al., 2007). In human prostate, HOXB13 is 
expressed in prostate luminal epithelial cells. In rodent models, it is expressed in the 
ventral prostate lobe and it is required for normal differentiation and secretory functions 
(Economides & Capecchi, 2003).   
Homeodomains of HOX genes bind to AT-rich DNA sequences, but these motifs are very 
abundant across the genome and therefore HOX proteins require additional cofactors for 
specificity. (Mann et al., 2009.) The best-known cofactors of HOX proteins are three 
amino acid loop extension (TALE) homeodomain proteins. MEIS, PKNOX 
(PBX/Knotted 1 homeobox), TGIF (TGFB Induced Factor Homeobox) and PBX (Pbx 
homeodomain protein) proteins belong to TALE superfamily, and they contain three 
amino acid insertions allowing them to cooperatively bind to other cofactors, which is 
one of the characteristics of TALE proteins. (Brechka et al., 2017.) Many mutations in 
HOXB13 that are associated with increased prostate cancer risk are located within the 




proteins and form multimeric complexes at gene promoters, thus regulating gene 
expression. However, TALE proteins also function independently from HOX proteins 
implicating that their role in disease development is extending beyond HOX protein 
regulation. (Mann et al., 2009.) 
The relationship between HOXB13 and AR has been studied since they both are 
expressed in prostate cells. However, the data obtained from these studies is quite 
controversial. The expression of HOXB13 is thought to be independent from androgen 
signaling as shown by studies made with mice, where HOXB13 mRNA accumulation 
remained following castration (Sreenath et al., 1999). HOXB13 also regulates cellular 
responses to androgen by interacting with the DNA binding domain of AR, and this 
interaction leads to inhibition of transcription of the genes containing androgen response 
element (ARE). In addition to its inhibitory effects, HOXB13 and AR can form a complex 
and bind to promoters specific for HOXB13 (Norris et al., 2009). HOXB13 can also 
inhibit PCa cell growth by functioning as a repressor of AR signaling. Jung et al. reported 
that HOXB13 suppressed AR activity in a dose-responsive manner and that it also 
suppressed the growth of LNCaP cells, which is an androgen-sensitive cell line, whereas 
in AR-negative CV-1 cells, it did not have similar effects. HOXB13 has also been shown 
to contribute to cell cycle arrest. Ectopic expression of HOXB13 decreased Cyclin D1 
levels by inducing its degradation by ubiquitination, resulting in cell growth inhibition 
due to reduced phosphorylation of the retinoblastoma protein (pRB) and stabilization of 
the pRB-E2F complex. Consistent with these results, depletion of HOXB13 expression 
led to an increase in cyclin levels, stabilization of E2F and increase in pRB 
phosphorylation. (Hamid et al., 2014.) On the contrary, under androgen-free conditions, 
expression of HOXB13 seems to inhibit the expression of p21, a TSG, leading to 
promotion of E2F signaling and cell cycle progression (Kim et al., 2010). Studies 
performed by Sipeky et al. have also demonstrated the synergistic effects of HOXB13 and 
CIP2A (cancerous inhibitor of PP2A), inhibitor of tumour suppressor PP2A (Protein 
Phosphatase 2A). HOXB13 binds to CIP2A and promotes its transcription leading to PCa 
progression. These observations implicate that HOXB13 has both oncogenic and tumour 
suppressing functions.  
The germline mutation HOXB13(G84E) was identified by Ewing et al. in 2012 within 
familial prostate cancers. This mutation is located in exon 1 and is a result of guanine (G) 
to adenine (A) substitution at position 251 of the DNA sequence. This substitution leads 




the protein sequence. This mutation is in the first MEIS interaction domain, however, 
Johng et al. demonstrated in their studies, that this germline mutation does not interfere 
with the HOXB13-MEIS1 interaction. They also demonstrated with expression analyses 
and co-immunoprecipitation (co-IP) assays, that both HOXB13 and MEIS1 are expressed 
and form a stable complex in both normal and PCa epithelial cells. 
The G84E mutation is a Finnish founder mutation, and it has been shown to significantly 
increase PCa risk (Ewing et al., 2012; Xu et al., 2013). The frequency in Finnish familial 
prostate cancer cases is 8,4 %, and it contributes to early onset of cancer and high PSA 
levels (Laitinen et al., 2013). The mutation has also been associated with early onset of 
familial PCa cases worldwide (Breyer et al., 2012). Analysis performed by Breyer et al. 
also revealed that the mutation carrier frequency was higher among cases with higher 
Gleason score, but the results were not statistically significant. Studies performed by 
Storebjerg et al. however concluded that the germline mutation carriers in Danish men 
had higher Gleason score and that the mutation may be associated with aggressive PCa. 
Other HOXB13 variants (Y88D, L144P, G216C, R217C, and R229G) that increase PCa 
risk have been identified in U.S. Caucasians (Ewing et al., 2012), and other germline 
mutations have been identified in non-Northern Europeans. Because the G84E mutation 
is mostly present in the European and Caucasian populations, studies about other 
HOXB13 mutations predisposing to PCa in non-Caucasian populations are needed. 
(Brechka et al., 2017.) 
Even though the HOXB13(G84E) variant was identified almost a decade ago, its function 
and mechanism in PCa development remains elusive. It has been suggested to result in 
increased HOXB13 protein stability which would increase the transcription of its 
downstream targets (Chandrasekaran et al., 2017). Cardoso et al. reported that the variant 
phenotype does not differ from wild type (WT) in apoptosis or proliferation rates, 
indicating that there is still controversy in the field regarding the molecular function of 
this variant. 
This is why functional studies on the mutated HOXB13 are needed to elucidate the 
transcriptional impacts of its target genes and how this leads to tumour initiation within 







CRISPR-Cas9 is an adaptive immune system against invading viruses in bacteria and 
archaea. CRISPR are the most widely distributed family of short noncoding DNA repeats 
among prokaryotes. The common features of these repeats are that they are composed of 
direct repeats and are separated by nonrepetitive spacer sequences, which are often 
located adjacent to cas (CRISPR-associated) genes. (Treangen et al., 2009.) 
The first findings of CRISPR-sequences were reported in 1987 in studies with the iap 
(alkaline phosphatase) gene of Escherichia coli (Ishino et al., 1987). Approximately ten 
years later, these repetitive sequences were described as Short-sequence DNA Repeat 
(SSR) (Van Belkum et al., 1998). The term CRISPR became generally accepted in 2002 
among scientists working on the subject (Jansen et al., 2002). 
In 2000, Mojica et al. suggested that these Short Regularly Spaced Repeats (SRSRs), as 
they described them, in bacteria and archaea are functionally related, but their 
physiological relevance was not known until in 2005 thanks to DNA sequencing. Mojica 
et al. showed that CRISPR spacers are derived from already existing sequences which are 
chromosomal or within transmissible genetic elements. These extrachromosomal 
elements showed a relationship between CRISPR and immune defense against specific, 
targeted DNA. Viruses containing this targeted DNA were shown to be unable to infect 
the cells containing the spacer sequence identical to the viral sequence. However, they 
did succeed to infect closely related strains lacking the specific CRISPR spacer. In 
addition, plasmids transferred among various species could not be maintained in members 
with the specific spacer even though the species belonged to same phylogenetic group. In 
2007, the CRISPR-Cas system was proven to be a part of the adaptive immunity of 
prokaryotes. Barrangou et al. reported that the spacer derived from phage DNA that is 
integrated into specific host genomic loci called the CRISPR-array, provides resistance 
specific for the phage, and that the bacteria can quickly adapt to certain population of 
phages by inserting new spacers.  
1.3.2 Classification of CRISPR-Cas systems 
CRISPR-Cas systems can be divided into two classes which are further divided into 
subclasses. Class 1 systems contain multi-Cas protein complexes and consists of subtypes 




consists of subtypes II, V and VI. (Hille et al., 2018.) In addition to differences in Cas-
proteins between class I and II, these classes and their subtypes differ in the way of 
processing CRISPR-RNA (crRNA), and their targets can be either DNA or RNA. Generic 
organization of CRISPR-Cas classes are presented in figure 8.  
  
Figure 8 Classification of the CRISPR-Cas systems. Systems are divided into two classes: class 
1 and class 2. Class 1 has multiprotein Cas complexes and is further divided into types I, III and 
IV. Class 2 systems use only one effector Cas protein and is further divided into type II, V and VI. 
Adapted from Makarova et al. (2020). 
In class 1 systems, proteins needed in the interference consists of multiple Cas-proteins: 
Cas3, which can be sometimes fused to Cas2, Cas5, Cas8, Cas10 and Cas11. These 
proteins function in different combinations in different subtypes, whereas in class 2 
systems, interference is performed by one single effector protein: Cas9 in subtype II, 
Cas12 in subtype V and Cas13 in subtype VI. (Makarova et al., 2020.) There are also 
common elements in different subtypes of CRISPR-Cas systems, such as Cas1 and Cas2, 




There are clear trends in the distribution of different classes and their types. Class 1 is 
more abundant than class 2, whereas class 2 is almost exclusively present in bacteria and 
not in archaea, which can be explained by the RNase III needed in pre-crRNA processing 
that is not present in archaea. (Makarova et al. 2020.)  
This thesis will mostly focus on the type II system and its applications.  
1.3.3 Mechanism of action 
The adaptive immunity of CRISPR-Cas9 is occurring in three stages: insertion of the 
spacer sequence into the CRISPR array, transcription of crRNA and mature crRNA-
directed cleavage of foreign DNA sites complementary to the spacer sequence by Cas. 
These stages are called adaptation, expression and interference, and they are present in 
all types of systems of both class 1 and 2 (Figure 9). (Hille et al., 2018.) 
 
Figure 9 Mechanism of the CRISPR-Cas system. The mechanism has three basic steps. The first 
step is adaptation, where new spacers are acquired into the CRISPR array. The second step is 




the final step is interference where invasive sequences are recognized and cleaved by Cas 
proteins. R=repeat, S=spacer. Adapted from Rath et al. (2015). 
Adaptation, also known as the spacer acquisition, is the process in which bacteria or 
archaea gain specific genetic memory towards the infection, and the reason why CRISPR-
Cas immunity is adaptive (Hille et al., 2018). Adaptation includes several steps which are 
detection of the mobile genetic element (MGE), selection of protospacer and processing 
it, and integration of the spacer into the CRISPR array. Protospacers are viral sequences 
which are located adjacent to protospacer adjacent motif (PAM) sequences. The 
adaptation machinery, consisting of Cas1 and Cas2, recognizes the PAM sequence 
located in the viral DNA. However, in type II systems, Cas9, Csn2 accessory protein and 
trans-activating crRNA (tracrRNA) are also essential components of the spacer 
acquisition (Heler et al., 2015). The PAM sequence recognition is essential for spacer 
acquisition, but also for interference. Protospacer is excised from the target DNA and 
inserted into the CRISPR array (Hille et al., 2018.)  
The next step after spacer acquisition is expression of the crRNA and processing it. The 
newly acquired spacer is transcribed into pre-crRNA and processed by Cas proteins and 
additional RNAses. In order to process the pre-crRNA into mature crRNA, type II system 
requires RNase III, Cas9 and tracrRNA. (Deltcheva et al., 2011.) The tracrRNA is a 
noncoding RNA required for initiation of the pre-crRNA processing by activating RNase 
III (Jinek et al., 2012), and it is almost exactly complementary with the pre-crRNA. This 
enables RNase III to recognize it and process it into a mature crRNA needed in the 
interference (Deltcheva et al., 2011).  
In interference, which is the final step of CRISPR adaptive immunity, foreign viral DNA 
is cleaved by Cas nuclease. Type II systems are simple in contrast to class 1 systems 
requiring cascades since they only use Cas9 endonuclease and its cofactors. crRNA and 
tracrRNA function as a guide RNA (gRNA) by base pairing with Cas9 as a RNA-duplex. 
This complex recognizes the target site where PAM sequence is located and cleaves both 
strands forming a DSB. (Jinek et al., 2012.) 
Type II system is widely used in biotechnological applications (see section 1.3.5), but 




1.3.4 Cas9 structure and function 
This chapter will focus on crystal structure of Streptococcus pyogenes Cas9. Cas9 
contains two nuclease domains (HNH and RuvC), two recognition domains (REC1 and 
2) and PAM-interacting domain (PI). It consists of two lobes which are recognition (REC) 
and nuclease lobe (NUC). (Nishimasu et al., 2014.) The two lobes are connected by a 
long α-helix called bridge helix (BH). The NUC lobe contains both nuclease domains, 
HNH and RuvC, needed for cleavage of both the complementary and noncomplementary 
strand, and it also contains the PI domain required for interaction with PAM sequence. 
The REC lobe is required for binding the sgRNA and the target DNA. The interaction 
between RuvC and PI domain forms a positively charged surface where negatively 
charged 3’-tail of the sgRNA can bind (Figure 10). (Nishimasu et al., 2014; Jinek et al., 
2014.) 
 
Figure 10 Structure of the Streptococcus pyogenes Cas9. Figure illustrates the structure of 
SpCas9-single guide RNA (sgRNA)-DNA complex. It consists of two lobes: nuclease lobe (NUC) 




In this structure described by Nishimasu et al., SpCas9 binds sgRNA and target DNA, but 
it is in inactive state (apo state), and additional cofactors are not bound to it. Once the 
cofactors are bound, conformation change into active state occurs and the target DNA is 
cleaved (Jinek et al., 2014). 
The REC lobe consists of REC1 and REC2 domains. REC1 contains elongated α-helical 
structure consisting of 25 α-helices and two β-sheets, whereas REC2 possess a six-helix 
bundle structure. The structure of REC lobe seems to be unique, indicating its specificity 
for Cas9. REC2 is not mandatory for DNA cleavage since a Cas9 mutant lacking it has 
been shown to retain Cas9 activity. However, REC1 is critical for DNA cleavage. 
(Nishimasu et al., 2014.) 
HNH domain in the NUC lobe is responsible for cleavage of the DNA sequence 
complementary to crRNA and RuvC domain is responsible for cleaving the 
noncomplementary strand, resulting in DSB (Jinek et al., 2014). HNH domain consists of 
two-stranded antiparallel β-sheet and four α-helices. The active site has three catalytical 
amino acid residues: His41, Asp40 and Asn62, and additional Mg2+ for cleaving the 
substrates with a single-metal mechanism. (Nishimasu et al., 2014.) RuvC domain is 
formed by a mixed six-stranded β-sheet, seven α-helices and two two-stranded 
antiparallel β-sheet, and the active site contains four catalytical amino acid residues: 
Asp7, Glu70, His143 and Asp146, and two Mg2+-ions for cleaving the noncomplementary 
strand with two-metal mechanism (Nishimasu et al., 2014).  
The site specific DSB can be repaired by two different mechanisms: either by 
nonhomologous end joining (NHEJ) or homologous recombination. In NHEJ, broken 
ends of the DNA fragments are joined before they drift apart. However, NHEJ is more 
prone to errors and it usually can lead to undesired insertions or deletions of nucleotides. 
In homologous recombination, DNA helix is opened and the damaged strands invade into 
homologous DNA duplex. Homologous duplex can be for example from the sister 
chromatid or a vector. The homologous strand is then used as a template for repairing the 
DSB. Homologous recombination requires multiple proteins, and BRCA1 and BRCA2 
are well-known examples of these. Because of the template homology required in the 
process, less errors usually occur compared to NHEJ. (Strachan & Read, 2019.)  
The PI domain in the NUC lobe is also unique for Cas9 protein family, and it consists of 
seven α-helices, one three-stranded antiparallel β-sheet, one five-stranded antiparallel β-




function in recognition of the PAM sequence, functional studies have implicated its 
importance in Cas9 nuclease activity since the deletion of the domain prevents Cas9 from 
cleaving the DNA (Nishimasu et al., 2014). 
1.3.5 Applications 
The discovery of CRISPR-Cas9 and its development into a genome editing tool has made 
it one of the most commonly used tools in genome editing. In 2012, Doudna and 
Charpentier showed that CRISPR-Cas9 introduces a DSB in the target DNA (Jinek et al., 
2012), and later they showed that the tracrRNA:crRNA complex could be fused into a 
chimeric sgRNA, which made CRISPR-Cas9 even more convenient for genome editing, 
since it only required two components: Cas9 and a sgRNA. The HDR process can be used 
to introduce a desired edit into the target site by an additional exogenous donor DNA 
(dDNA) template. 
Now CRISPR-Cas9 is widely used within different organisms because it has many 
advantages when compared with other gene editing technologies. It does not require as 
much labor and is not as expensive compared to for example endonuclease-based zinc 
fingers or transcription activator-like effector nucleases (TALENs), which demand re-
engineering for every new target sequence. Cas9 is identical in all cases so only sgRNA 
sequences require editing if new target needs to be identified, also, CRISPR-Cas9 has the 
potential of editing multiple loci at the same time. (Lino et al., 2018.)  
CRISPR-Cas systems have been widely used within eukaryotes, but not that much in 
bacteria due to their lack of capacity to fix DSBs. If they had the capacity to repair them 
after invader attack, the invader would persist. However, different techniques promoting 
homologous recombination of linear DNA fragments in bacteria have been developed 
(Luo et al., 2016).  
CRISPR-Cas9 has provided quite a simple way to genetically engineer animals and thus, 
helped to understand molecular mechanisms underlying different diseases. It can also be 
exploited for the treatment of diseases, which have a genetic origin. The method is for 
example widely used in the research of cardiovascular, metabolic and neurodegenerative 
diseases, and cancer. (Lino et al., 2018.) 
Despite the many advantages of CRISPR-Cas9 and its applications in genome 
engineering, there are limitations and challenges. DSB repair processes can easily lead to 




may also lead to off-target effects when highly homologous sequences can also be cleaved 
in addition to the desired target, and this can lead to chromosomal rearrangements and 
mutations. (Li et al., 2020.) HDR efficiencies also vary among different cell types, and it 
is active during only specific phases of the cell cycle. It also competes with NHEJ in the 
repair of DSBs and usually is outcompeted by it. (Porto et al. 2020.) 
These limitations and challenges restrict the potential of CRISPR-Cas to be exploited for 
therapeutic purposes. Ideal therapeutical tools for genome editing would possess high 
editing efficiency for the target site and minimal off-target effects. Therefore, enhancing 
the efficiency and precision of CRISPR-Cas9 or developing new more precise tools is of 
interest for researchers.  
By mutating either the HNH or the RuvC domain of the Cas9, researchers have created 
the Cas9 nickase which only cleaves one strand. Nicking only one strand does not make 
a DSB, and therefore these editing methods where Cas9 nickases are used have less 
undesired edits like insertions and deletions. Base editing and prime editing are examples 
of these tools, where only one strand is nicked instead of introducing DSBs and the 
desired edit is introduced without an additional dDNA template. (Anzalone et al. 2019; 
Porto et al. 2020.) 
1.3.6 Base editing 
Base editing is a genome editing method using CRISPR components and other enzymes 
to introduce mutations into DNA sequence without causing DSBs. Base editing does not 
cleave the nucleic acid backbone because it chemically alters the target site. Base editors 
can target both DNA and RNA. (Porto et al., 2020.)  
DNA base editors can be divided into cytosine base editors (CBEs) and adenine base 
editors (ABEs), and they can introduce permanent transition mutations (CT, TC, 
AG and GA) with high efficiencies. CBEs use cytidine deaminase to convert 
cytosine into uracil resulting in conversion of G-C bp to A-T bp, whereas ABEs mediate 
editing with inosine-containing intermediate resulting in conversion of A-T bp to G-C bp. 
RNA base editors are divided according to the modification they introduce. (Porto et al., 
2020.) 
Base editing offers promising alternative for genome editing without introducing DSBs 
and it can efficiently install all four transition mutations. However, it lacks the ability to 




TA) and targeted deletions or insertions, and this reflects the need for alternative editing 
tools. (Anzalone et al., 2019; Porto et al., 2020.) 
1.3.7 Prime editing 
Prime editing is a novel genome editing method described by Anzalone et al. in 2019. 
Prime editing uses a catalytically impaired Cas9 endonuclease fused with reverse 
transcriptase (RT) and a prime editing guide RNA (pegRNA) containing the primer 
binding site (PBS) and template sequence for RT with the desired edit (Figure 11).  
 
Figure 11 Illustration of the prime editing complex. Prime editing guide RNA (pegRNA) is 
coloured in green. Prime editor (PE) consisting of reverse transcriptase (RT) and Cas9 domain 
is nicking the template strand and introducing the mutation by using the pegRNA as a template. 
After introducing the nick, mutation is introduced by RT using the pegRNA as a template. PE 
complex also contains green fluorescent protein (GFP) as a reporter. Adapted from Anzalone et 
al. (2019). 
The mechanism is that the prime editor (PE), a fusion protein, nicks the target DNA 
sequence and exposes a 3’-hydroxyl group. This hydroxyl group is then used to initiate 
reverse transcription of the pegRNA template. This results in an intermediate containing 
two flaps of DNA: a 3’-flap containing the desired edit and a 5’-flap containing the 
unedited DNA. Endogenous 5’-exo- or endonuclease is used to cleave this flap and 3’-




edited strand and forces the cells to use the prime edited strand as a template (Figure 12). 
(Anzalone et al., 2019.) 
 
Figure 12 The mechanism of prime editing. Prime editing guide RNA (pegRNA) and prime editor 
(PE) are introduced to target DNA and after recognition of the protospacer adjacent motif (PAM) 
a nick is introduced by Cas9 nickase. Primer binding site (PBS) in the pegRNA is hybridizated to 
the target strand and desired edit is introduced with reverse transcriptase (RT) using the pegRNA 




3’ flap containing the edit and a 5’ flap without the edit. After cleavage of the 5 flap, ligation and 
DNA repair of the non-edited strand in the target site, target DNA containing the desired edit is 
achieved. Adapted from Anzalone et al. (2019). 
Anzalone et al. used prime editing to install and correct the primary genetic alterations 
causing sickle cell disease and Tay-Sachs disease. Sickle cell disease is usually caused 
by transversion resulting in E6V in hemoglobin subunit beta (HBB) whereas Tay-Sachs 
disease by a 4 bp insertion into hexosaminidase subunit alpha (HEXA). They installed the 
HBB E6V into human embryonic kidney cells (HEK293T cell line) resulting in 44 % 
efficiency and 4,8 % insertions and deletions (indels). Correcting this mutation back to 
WT resulted in 26 – 52 % efficiency with 2,8 ± 0,7 % indels. They installed the 4 bp 
insertion into HEXA with 31 % efficiency and 0,8 % indels and reverted this insertion 
back to WT with 33 % efficiency and 0,32 % indels.   
In order for prime editing to work, pegRNA spacer complementarity with target DNA is 
required for the Cas9 domain binding and PBS of pegRNA needs to be complementary 
with the target DNA for the initiation of reverse transcription. The RT product also needs 
to be complementary with the target DNA for flap resolution (Anzalone et al., 2019). 
Anzalone et al. tested the ability of these hybridization steps to reduce off-target prime 
editing compared to conventional CRISPR-Cas9 editing methods requiring only gRNA 
complementarity. They concluded that prime editing introduces much lower off-target 
editing.  
This method does not need additional donor DNA’s or DSBs such as conventional 
CRISPR-Cas9. DSBs can easily introduce undesired byproducts such as translocations or 
mixtures of products, and it can also activate p53 (Haapaniemi et al., 2018). Even though 
DSB-mediated genome editing has a promising future especially in the therapeutic 
applications, alternative precision editing methods are constantly explored, and prime 
editing is a promising tool for this purpose.  
Base editing introduces efficiently single-nucleotide variants into DNA without DSBs 
(Porto et al., 2020). However, it can currently perform only the four transition mutations 
(pyrimidine to pyrimidine or purine to purine) and not the transversion (purine to 
pyrimidine or pyrimidine to purine) mutations in mammals. Base editing also cannot 
perform targeted deletions or insertions whereas prime editing can. (Anzalone et al. 2019; 
Porto et al. 2020.) Anzalone et al. compared prime editing and base editing in three 




depending on the desired locus, they functioned in a complementary fashion. Current base 
editors are more efficient and generate fewer indels. However, prime editing introduces 
less off-target editing and it can perform in the absence of suitably positioned PAM site.  
Currently there are not many publications considering the method. Prime editing has been 
performed in plants such as rice and maize, but it has succeeded with only small 
efficiencies (Jiang et al., 2020; Lin et al., 2020), and in Drosophila melanogaster (Bosch 
et al., 2021) in addition to experiments performed by Anzalone et al.  
Prime editing offers a promising addition to the precision genome editing toolbox by 
allowing DNA specificity and editing efficiency and by enabling all 12 possible base-to-
base conversions and indels. Base editors can also install transition mutations and 
currently, they are more efficient and introduce fewer indels if the target locus is located 
within the canonical base editing window. However, base editing is limited to only 
transitions and it introduces unwanted bystander edits more than prime editing. Prime 
editing eliminated the need for DSBs and additional donor DNAs which are one of the 
challenges when using conventional CRISPR-Cas9 genome editing methods. Using 
prime editing still has many challenges and it may not be able to perform larger DNA 
insertions and deletions. Using RT might also incorporate unwanted, random cDNAs and 
pegRNAs and sgRNAs might confer problems when it comes to RNA-stability. However, 
more studies on prime editing within different cell lines are needed to optimize the 
method. Possibly, in the future it has the potential to be exploit for therapeutic 
applications in the treatment of genetic disease by enabling transitions, transversions and 











2. Aim of the thesis 
The aim of the thesis was to generate tools to generate HOXB13G84E cellular models with 
prime editing. Four different prime editing plasmids were generated: three pegRNAs with 
PBS lengths of 10 nt, 13 nt and 16 nt, and an additional sgRNA for nicking the non-edited 
strand. A plasmid encoding HOXB13 was also generated and the G84E mutation was 
introduced with site-directed mutagenesis by PCR, and this was used as a positive control 
in droplet digital PCR (ddPCR) assay. Western blot was performed to protein lysates of 
PCa and RWPE-1 cell lines to determine if they express HOXB13, and based on the 
results, a cell line for the experiments was chosen. The aim was to optimize the PBS of 
the pegRNA by determining which of the three was the most efficient, and if prime editing 
could be used for introducing the G84E mutation in the chosen cell line for further 
research. In the future, the most suitable construct can be used to generate cellular models 
of the germline mutation G84E in HOXB13 for elucidating its function and mechanism 














3. Materials and methods 
3.1 Generation of the plasmid constructs 
3.1.1 pegRNA plasmids 
The pU6-pegRNA-GG-acceptor plasmid was a gift from David Liu (Addgene plasmid # 
132777) (Anzalone et al., 2019). The plasmid was digested in a PCR tube containing 30 
µl of reaction mix [2000 ng plasmid, 20 U Bsa1-HFv2 (NEB), 1X CutSmart buffer (NEB, 
50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate, 100 µg/ml 
BSA, pH 7.9)]. The reaction mix was incubated for 5 h at 37 ᵒC. Blue loading dye was 
added to sample (NEB, 2.5% Ficoll®-400, 11 mM ethylenediaminetetraacetic acid 
(EDTA), 3,3 mM Tris-HCl, 0,017 % sodium dodecyl sulfate (SDS), 0,015 % 
bromophenol blue, pH 8) and reaction products were separated on a 1 % agarose gel (100 
V). The plasmid backbone was extracted from the gel with NucleoSpin Gel and PCR 
Clean-up kit (Macherey-Nagel) according to its protocol for DNA extraction from 
agarose gels. The DNA concentration was measured with NanoDrop One/OneC 
Microvolume UV-Vis Spectrophotometer (ThermoFisher Scientific).  
Oligonucleotides (Integrated DNA technologies) for the pegRNAs (Table 1, 
oligonucleotides 1 - 6) were annealed by combining them in a PCR tube with total volume 
of 25 µl [4 µM top oligonucleotide, 4 µM bottom oligonucleotide, annealing buffer (9,2 
mM Tris-Cl pH 8.5, 46 mM NaCl)]. Reaction mixes were heated at 95 ᵒC for 5 min in a 
thermocycler and gradually cooled to 22 ᵒC (0,1 ᵒC/s). Annealed oligonucleotides were 
diluted to 1 µM except for the sgRNA scaffold, which was phosphorylated in a PCR tube 
with a total volume of 25 µl [1 µM sgRNA scaffold oligonucleotide duplex, 5 U T4 PNK 
(NEB), 1X T4 DNA ligase buffer (70 mM Tris-HCl, 10 mM MgCl2, 5 mM dithiothreitol 
(DTT), pH 7.6, NEB)]. Phosphorylation was done by incubating the reaction mix at 37 
ᵒC for 1 h.  
pegRNAs were assembled with Golden Gate cloning reaction. Reactions were performed 
in PCR tubes with total volumes of 10 µl [30 ng digested pU6-pegRNA-GG-acceptor 
plasmid vector, 1 µM annealed protospacer oligonucleotides, 1 µM annealed pegRNA 
3´-extension oligonucleotides, 1 µM annealed sgRNA scaffold oligonucleotides, 5 U 
BsaI-HFv2 (NEB), 1000 U T4 DNA ligase (NEB), 1X T4 DNA ligase buffer]. Reaction 
was performed in a thermocycler with the following program: 5 min at 16 ᵒC and 5 min 




3.1.2 gRNA plasmid for nicking the non-edited strand 
The MLM3636 plasmid was a gift from Keith Joung (Addgene plasmid # 43860). This 
plasmid was used for creating the MLM3636-HOXB13-G84E-3GtoA+97nick plasmid, 
which encodes a gRNA targeting HOXB13. gRNA_HOXB13G84_3GtoA_+97nick 
forward (F) and reverse (R) oligos were annealed (0,5 µM of each oligo) in reaction 
volume of 20 µl by heating the mix to 95 ᵒC for 5 min and cooling to 10 ᵒC gradually (5 
ᵒC/min). The MLM3636 vector backbone had already been digested with Esp3I. The 
oligo duplex was ligated into the vector in reaction mix with total volume of 20 µl [150 
ng digested MLM3636 plasmid, 1 µl of double-stranded annealed oligos, 1X T4 DNA, 5 
U Esp3I (NEB), 1000 U T4 DNA ligase]. Reaction was performed in a thermocycler with 
the following program: 5 min at 16 ᵒC and 5 min at 37 ᵒC for 8 cycles, 15 min at 37 ᵒC 
and 15 min at 80 ᵒC, hold at 12 ᵒC. 
3.1.3 WT pcDNA3-HOXB13 
cDNA synthesis was performed for RNA extracted from LNCaP native cells with 
iScript™ Select cDNA Synthesis Kit (Bio-Rad) with a 20 µl reaction mix [1 µg of total 
RNA, 1X iScript select reaction mix, 2 µl Oligo(dT)20 primer, 1 µl iScript reverse 
transcriptase]. The reaction mix was incubated for 90 min at 42 °C and for 5 min at 85 
°C. The PCR reaction for cloning the HOXB13 insert from cDNA was performed in a 
reaction mix with total volume of 25 µl [1X CloneAmp HiFi PCR Premix (Takara), 2 µl 
LNCaP cDNA, 0,3 µM primer HOXB13_In_F1, 0,3 µM primer HOXB13_In_R1 
(Integrated DNA technologies)]. PCR reaction was performed with the following 
program: 98 ᵒC 10s, 55 ᵒC 15 s, 72 ᵒC 5 min for 35 cycles and hold at 10 ᵒC. 
Linearization and removal of NLS-mCherry from pcDNA3-mCherry-NLS was made 
with PCR. The reaction mix was prepared into a total volume of 25 µl [1X CloneAmp 
HiFi PCR Premix, 10 ng template, 0,3 µM primer pcDNA3-Ano7_InF3, 0,3 µM primer 
pcDNA3_R2 (Integrated DNA technologies)]. The PCR reaction was run with the 
following program: 98 ᵒC 10s, 55 ᵒC 15 s, 72 ᵒC 5 min for 35 cycles and hold at 10 ᵒC.  
Both PCR reaction products were separated on a 1 % agarose gel (100 V) and the correct 
size DNA was cut from the gel and extracted with the NucleoSpin Gel and PCR Clean-




In-Fusion cloning reaction was done for HOXB13 insert and pcDNA3 backbone in a total 
reaction volume of 10 µl [1X In-Fusion HD Enzyme Premix, 150 ng pcDNA3 vector, 50 
ng HOXB13 insert]. Reaction mix was incubated for 15 min at 50 ᵒC and placed on ice.  
Removing the intron from pcDNA3-HOXB13 was done by PCR in a reaction mix with 
total volume of 25 µl [10 ng template plasmid, 1X CloneAmp HiFi PCR Premix, 0,3 µM 
primer HOXB13intronDel_F1, 0,3 µM primer HOXB13intronDel_R1 (Integrated DNA 
technologies)]. The PCR reaction was run with the following program: 98 ᵒC 10s, 55 ᵒC 
15 s, 72 ᵒC 6 min for 35 cycles and hold at 10 ᵒC. The PCR-product was run on a 1 % 
agarose gel (100 V) and PCR-clean-up was performed to the pcDNA3-HOXB13 plasmid 
without the intron. In-Fusion cloning was performed on the cleaned plasmid incubating 
the reaction mix with a total volume of 10 µl [1X In-Fusion HD Enzyme Premix, 50 ng 
pcDNA3-HOXB13] for 15 min at 50 ᵒC following transformation to Stellar bacteria. 
Undesired P144L SNP was removed with PCR-mutagenesis as described in section 3.1.4, 
but primers that were used were HOXB13_P144L_F1 and HOXB13_P144L_R1 
(Integrated DNA technologies). 
3.1.4 pcDNA3-HOXB13_G84E 
Site-directed mutagenesis was performed on the WT pcDNA3-HOXB13 in a reaction mix 
of 50 µl [1X CloneAmp HiFi PCR mix, 0,2 µM primer HOXB13_G84Emut_F1, 0,2 µM 
primer HOXB13_G84Emut_R1 (Integrated DNA technologies), 10 ng template]. PCR 
reaction was run with the following program: 98 ᵒC 10s, 65 ᵒC 15 s, 68 ᵒC 6 min for 18 
cycles.  10 µl of PCR-product was run on 1 % agarose gel (100 V) and PCR-clean-up was 
performed to the rest of the product. 
DpnI treatment was performed on the cleaned product in a 50 µl reaction mix [1 µg 
plasmid, 1X CutSmart buffer, 20 U DpnI]. The mix was incubated for 1 h at 37 ᵒC and 
PCR-clean-up was performed.  
3.1.5 Plasmid isolation and sequencing 
Plasmids were transformed into 5α-competent E.coli (NEB). Transformation was 
performed according to the protocol of NEB. Transformed bacteria were plated on LB 
plates containing 100 µg/ml of ampicillin and grown overnight at 37 °C. 
For plasmid isolation, a E.coli colony from the LB agar -plate was selected for liquid 




(300 rpm, 37 °C). The following day, plasmids were isolated with NucleoSpin kit for 
plasmid DNA purification (Macherey-Nagel) according to the manufacturer’s 
instructions.  
Glycerol stocks were made from each plasmid (1:1 liquid culture and 65 % glycerol) and 
stored at -80C. Samples were prepared for sequencing according to instructions 
(Eurofins) and sent to Eurofins Genomics for Sanger sequencing. 
Table 1 Primer/oligonucleotide table. Primers/oligonucleotides used for generating the 
pegRNAs, sgRNa and pcDNA3-HOXB13. 
 
 
3.2 Cell lines and culture conditions 
3.2.1 Cell lines and growth conditions 
LNCaP (American Type Culture Collection, ATCC), RWPE-1 (ATCC) and PC-3 
(ATCC) cells were cultured at +37 °C and 5 % CO2- concentration. Trypsin-EDTA (0,25 
%) (Gibco, Thermo Fisher) was used for detaching the cells, and phosphate buffer saline 
(PBS) was used for washing the cells.  
LNCaP cells were cultured in RPMI-1640 medium (ATCC, 30-2001), PC-3 cells in F-
12K medium (ATCC-30-2004). Both media contained 10 % fetal bovine serum (FBS) 
and 5 % penicillin and streptomycin (PenStrep). RWPE-1 cells were cultured in 




pituitary extract (BPE), 5 ng/ml epidermal growth factor (EGF) and 5 % PenStrep. All 
cell lines were cultured in Corning® T-75 flasks. 
3.2.2 Transfection of cell lines and cell sorting 
Transfection was performed with Invitrogen Lipofectamine 3000 reagent (ThermoFisher 
Scientific) according to its protocol. Following amounts of plasmids per well of 12-well 
plate were used in the transfections: 3 µg of pCMV-PE2-P2A-GFP (a gift from David 
Liu (Addgene plasmid # 132776) (Anzalone et al., 2019), 1 µg of pU6-pegRNA-
HOXB13-3GtoA-PBS10/13/16-Ext13, 0,33 µg MLM3636-HOXB13-G84E-
3GtoA+97nick. GFP-positive cells were sorted with a Sony SH800 Cell sorter. 
 
3.3 Determination of cell lines expressing HOXB13 with 
Western blot 
3.3.1 Protein lysate preparation 
Protein lysates were prepared by removing media from the cell culture, washing with PBS 
and by adding 200 µl of radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-Cl, 
pH 8; 150 mM NaCl; 1 % Triton-X; 0,5 % Sodium deoxycholate; 0,1 % SDS; protease 
inhibitor (Roche)). Cells were scraped and collected into microcentrifuge tubes and 
incubated for 30 min on ice. After incubation, cells were centrifuged for 20 min at 13000 
× g (+ 4 °C) and supernatant was collected.  
Protein concentration determination was performed with PierceTM BCA Protein Assay Kit 
(Thermo Scientific) according to kit protocol and BSA was used for making the standard 
curve. 
3.3.2 Western blot 
The protein amount of the cells was analyzed with Western blot. Protein samples were 
prepared by adding 30 µg of protein lysate, 1 × Laemmli sample buffer (65,8 mM Tris-
HCl, pH 6.8; 2,1 % SDS; 26,3 % (w/v) glycerol; 0,01 % bromophenol blue; 5 % β-
mercaptoethanol) and adjusting the volume to 20 µl. Samples were boiled at +95 °C for 
5 min and centrifuged shortly. 20 µl of sample/well was loaded to 4 – 20 % gradient gel 




(Bluestar Prestained Protein Marker Plus, Nippon Genetics). Gel was run with 100 V in 
running buffer (0,025 M Tris; 12,5 mM glycine; 0,1 % (w/v) SDS) for 1,5 h.  
After the gel run, proteins were transferred onto polyvinylidene fluoride (PVDF) 
membrane (Immobilon PVDF Membrane, Sigma Aldrich) with wet electroblotting 
system (Mini Trans-Blot Cell, BIO-RAD) with 70 V for 3 h (+4 °C) in transfer buffer 
(0,025 M Tris; 12,5 mM glycine; 0,1 % SDS; 20 % (v/v) ethanol). Membrane was blocked 
with 5 % milk in TBST for 1 h on a tube roller at room temperature (RT). The membrane 
was washed with TBST and incubated overnight with HOXB13 primary antibody (Cell 
signaling technology, D7N80 Rabbit mAb) diluted 1:1000 in TBST with 1 % BSA and 
0,02 % Na-azide at +4 °C. The membrane was washed three times with TBST for 5 min 
and incubated with horseradish peroxidase conjugated secondary antibody (Abcam, Goat 
anti-Rabbit IgG) diluted 1:10000 in TBST with 5 % milk for 2 h at RT. The membrane 
was washed three times as above and incubated with Western Bright Quantum 
chemiluminescent substrate for two min. The (Advansta) chemiluminescence was 
detected with a ChemiDoc imaging system (BIO-RAD). The images and protein band 
intensities were quantified with ImageJ (Schindelin et al., 2012). Normalization of the 
samples was made using β-actin as a loading control.  
 
3.4 Measuring prime editing efficiency with droplet 
digital PCR 
3.4.1 DNA isolation 
DNA from the transfected cells was isolated with Illustra blood genomicPrep Mini Spin 
Kit (GE Healthcare) according to the manufacturer’s instructions, but cells were washed 
with PBS for one additional time after detaching them.  
3.4.2 ddPCR assay 
Prime editing efficiency was measured with ddPCR. The reaction mix was prepared and 
each well contained 1 × ddPCR Supermix for Probes (No dUTP), 250 nM probe FAM 
(WT HOXB13, BIO-RAD), 250 nM probe HEX (HOXB13 G84E, BIO-RAD), 5 U 
HindIII HF and 40 – 150 ng sample (total volume 22 µl/well). Droplets were generated 




PCR was performed for droplets with the following program: 95 °C 10 min, 94 °C 30 s, 
56 °C 1 min, 98 °C 10 min and 4 °C hold. Steps 2 and 3 were repeated 40 times.  




4.1 Plasmid generation 
4.1.1 Three different pegRNA-plasmids were generated for 
optimizing the PBS 
The aim was to optimize the PBS length by generating three different pegRNA constructs 
with different lengths of PBS: one with 10 nt PBS, one with 13 nt PBS and one with 16 
nt PBS (Figure 13A). Plasmids were successfully generated by digesting the pU6-
pegRNA-GG-vector acceptor with BsaI (Figure 13A & B) and annealing the pegRNA 
spacer, pegRNA scaffold and pegRNA 3’ extension (containing the PBS) (Table 1), and 
by assembling the annealed components with pU6-vector backbone with Golden Gate 
cloning.  
After assembling the pegRNAs, they were grown in E.coli and extracted. Plasmids were 
sent for sequencing and the correct sequences of each pegRNA were verified with Sanger 






Figure 13 Plasmid map of pU6-pegRNA-HOXB13_G84E-3GtoA-PBS13-Ext13 and its 
generation process.  A= plasmid contains ampicillin resistance cassette (AmpR) and promoter 
for it, U6 promoter, origin of replication (ori), spacer, guide RNA (gRNA) scaffold, primer 
binding site (PBS) and reverse transcriptase (RT) template. Restriction sites for enzymes are 
shown in the picture. B= pU6 -GG-vector backbone was digested with BsaI and 2.2 kb pU6 
fragment was cleaned from 1 % agarose gel and used as a plasmid backbone for three different 
pU6-pegRNA-HOXB13_G84E-3GtoA-PBS10/13/16-Ext13 plasmids. C= Sanger sequencing 








4.1.2 sgRNA-plasmid was generated for nicking the non-edited 
strand at +97 bases from the prime editing site 
A plasmid for sgRNA was generated for nicking the non-edited strand at +97 bp from 
prime edited site to favor the repair of non-edited strand in the target DNA by using the 
newly edited strand as a template. gRNA oligonucleotides (Table 1) were successfully 
annealed and ligated into Esp31 digested MLM3636 vector backbone resulting in 
MLM3636-HOXB13_G84E.3GtoA+97nick -plasmid (Figure 14A).  
After transformation into E.coli for cloning and extraction, correct sequence were verified 
with Sanger sequencing (Figure 14B).  
 
Figure 14 Plasmid map of the MLM3636-HOXB13_G84E-3GtoA+97nick and result from 
Sanger sequencing showing the correct crRNA and gRNA scaffold sequence. A= The plasmid 
contains origin of replication (ori), ampicillin resistance cassette (AmpR) and its promoter, U6 
promoter for transcription of the gRNA scaffold. Transcribed gRNA is used for nicking the 
nonedited strand at 97 bp from the prime edited site, and this favors the repair of the nonedited 
strand in the target DNA by using the prime edited strand as a template. B=Results from Sanger 
sequencing verified that the plasmid is correct. Sequences of crRNA and gRNA scaffold can be 





4.1.3 The pcDNA3-HOXB13_G84E -plasmid was generated for a 
positive control for the mutation in the ddPCR assay 
A plasmid containing the HOXB13 cDNA was generated and the G84E mutation was 
later introduced with site-directed mutagenesis by PCR, and this was used as a positive 
control for the mutation in the ddPCR assay. cDNA was synthetized from LNCaP RNA 
and HOXB13 cDNA was amplified with PCR. pcDNA3 was used as a backbone and it 
was linearized and the NLS-mCherry was removed with PCR and gel electrophoresis 
(Figure 15A). The pcDNA3 backbone was of correct size (5,5 kb) but the size of the 
HOXB13 cDNA insert was approximately 1,8 kb even though it should be 884 bp (Figure 
15A). HOXB13 contains two exons, and they have one intron between them which is 949 
bp, so the results implicated that the intron was retained. The plasmid was assembled with 
In Fusion -cloning reaction and after cloning and extraction, samples were sent for 
sequencing. Sanger sequence verified that the intron was retained in HOXB13 between 
the two exons (Figure 15B).  
The intron was removed from pcDNA3-HOXB13 plasmid with PCR and same steps were 
repeated (Figure 15C). Sanger sequencing results showed that the intron was removed. 
However, the results revealed additional single nucleotide polymorphisms (SNP) in exon 
2 of the HOXB13 which was not noticed previously. Ewing et al. has previously reported 
that LNCaP cells have the L144P mutation in one allele. The L144P SNP was corrected 
and G84E mutation was introduced with PCR, and ultimately WT-pcDNA3-HOXB13 
and pcDNA3-HOXB13_G84E plasmids were generated (Figure 15D) and Sanger 





Figure 15 The pcDNA3-HOXB13 plasmid was generated and the G84E mutation was 
introduced so the plasmid could be used as a positive control of the mutation in the droplet 
digital PCR (ddPCR) assay. A= mCherry-NLS was removed from the pcDNA3 plasmid backbone 
with PCR and the HOXB13 insert amplified from cDNA. PCR products were run on a 1 % agarose 
gel and combined with a In Fusion -cloning reaction. The HOXB13 insert was ~1,8 kb even 
though it should be 949 bp, and results from Sanger sequencing revealed that the intron was 
retained between the two exons. B= DNA sequence of the HOXB13 cDNA insert with retained 
intron between the two exons. Transcription start codon and termination codon are illustrated 
with green and blue, the desired mutation site (G) in red and intron sequence with grey 
background. C= the intron was removed with PCR and the correct size of the product (6,2 kb) 
was verified by running it on a 1 % agarose gel. D= Site-directed mutagenesis introduced the 
G84E mutation in the wild type (WT) pcDNA3-HOXB13 plasmid. Both plasmids containing the 




verified with Sanger sequencing. Start and termination codons are illustrated in green and red 
and the mutation site with red. Exon 1 and 2 are illustrated with different colors.  
 
4.2 All PCa cell lines express HOXB13 
Western blot was performed on protein lysates of PCa cell lines (LNCaP, PC-3, vCaP, 
22Rv1, MDA PCa 2b) and a normal immortalized prostate epithelial cell line RWPE-1 to 
determinate which of them express HOXB13. A protein lysate from LNCaP cells 
transfected with the WT-pcDNA3-HOXB13 construct was used as a positive control. β-
actin was used as a loading control and the data was normalized with its signal. Results 
revealed that all PCa cell lines express HOXB13, whereas RWPE-1 does not (Figure 16). 
The MDA PCa 2b -cell line has the highest HOXB13 expression (2,5 ± 2,1), and PC-3 
(0,3 ± 0,2) and 22Rv1 (0,2 ± 0,1) have the lowest. The results are presented as a relative 
HOXB13 expression and normalized with LNCaP (LNCaP relative expression = 1). The 
results are consistent with the Broad Institute HOXB13 RNASeq data (Appendix Figure 
1) (https://portals.broadinstitute.org/ccle).  






Figure 16 Prostate cancer cell lines express HOXB13 and RWPE-1 does not. Western blot was 
performed on protein lysates of six different cell lines and for positive control of the protein (lysate 
extracted from LNCaP cells after 24 h transfecting them with pcDNA3-HOXB13 plasmid). β-actin 
was used as a loading control. The results from Western blot were normalized with loading 






4.3 Prime editing of LNCaP cells 
LNCaP cells were transfected with pegRNA-, sgRNA- and PE -plasmids. The PE and 
GFP is separated by a 2A self-cleaving peptide in the plasmid. This leads to separation of 
the PE and GFP proteins during translation and enables the enrichment of transfected 
cells with a cell sorter based on the GFP-signal.  
Only a small amount of cells was obtained from the sorting (Neg C: 12000, PBS10: 3200, 
PBS13: 4000, PBS16: 12000), and the cells grew very slowly and many of them died 
when transferred to a 96-well plate, and therefore, only a small amount of DNA was 
gained from the isolation (concentration was 8 ng/µl for DNA extracted from cells 
transfected with pegRNA-PBS13 and 30 – 40 ng/µl for others).  
4.4 Prime editing was successful in generating the 
HOXB13G84E mutation  
As shown by Anzalone et al., PBS length may have an impact on how efficiently prime 
editing occurs in the cells at different loci. The ddPCR assay was performed on DNA 
extracted from cells transfected with different pegRNA-constructs to measure if the PBS 
length affects prime editing efficiency at this specific locus. The assay was first performed 
for a positive control containing DNA isolated from LNCaP cells transfected with 
pcDNA3-HOXB13_G84E (Appendix Figure 2). The assay was done twice for the 
samples (two technical replicates) (Figure 17). The first time, smaller amount of template 
DNA was used (1 µl) but second time the amount was increased (5 µl).  
Results from the first assay (Figure 17A), showed that samples transfected with pegRNA-
PBS10 did not have the mutation (fractional abundance 0 %), and those transfected with 
pegRNA-PBS13 and pegRNA-PBS16 did (fractional abundance average 24,5 ± 10,4 % 
and 9,3 ± 1,0 %). 
The second assay (Figure 17B) showed similar results with pegRNA-PBS10 and 
pegRNA-PBS 16 samples (fractional abundances 0 % and 11,1 ± 1,5 %, respectively), 
but the efficiency of pegRNA-PBS13 was 46,3 ± 2,1 % this time. Fractional abundance 






Figure 17 Prime editing efficiencies with three prime editing guide RNAs (pegRNAs) 
containing different length primer binding sites (PBS) were checked with droplet digital PCR 
(ddPCR). A= results from first assay with smaller amount of template. B= results from second 
assay with five fold template amount. Assay contained two wells (replicates) of nuclease free 
water (NFW), positive control (Pos C, DNA from LNCaP cells transfected with pcDNA3-
HOXB13_G84E) and negative control (Neg C, cells transfected with only prime editor and not 
with pegRNA) and three wells per DNA sample extracted from LNCaP cells transfected with 
pegRNA with PBS of 10, 13 or 16 nucleotides.   
The average of all results from both assays showed that the pegRNA with PBS16 seems 
to work with 10,2 ± 1,5 % efficiency. The pegRNA with PBS13 seems to be working 
also, since the average of fractional abundance was 35,4 %, but the standard deviation 
was very high (13,7). PBS10, however does not seem to be working at all, since the 





Figure 18 Prime editing worked with two of the three generated prime editing guide RNAs 
(pegRNAs). Graph shows the average of fractional abundances of the G84E mutation in LNCaP 
cells transfected with prime editing plasmids. The pegRNA plasmids contained different length 
primer binding sites (PBS): 10, 13 or 16 nucleotides. Droplet digital PCR (ddPCR) assay was 
performed two times and both assays contained three technical replicates of the sample, and the 
average is from six technical replicates. Standard deviations can be seen in the graph.  
Because of the high variation in the results from pegRNA-PBS13 transfected cells, 
extracted DNA was amplified with PCR and sample was sent for Sanger sequencing. 
Results showed that the mutation was present, however, the WT was far more abundant 
compared to the mutation (Figure 19). The true efficiency of prime editing with pegRNA 
containing the 13 nt long PBS remains unclear. 
 
Figure 19 The wild type HOXB13 sequence is far more abundant than the mutation in LNCaP 
cells transfected with prime editing guide RNA (pegRNA) with primer binding site of 13 
nucleotides. DNA extracted from transfected LNCaP cells was amplified with PCR and a sample 






5.1 HOXB13 protein expression in prostate cell lines 
Western blot was performed on protein lysates and β-actin was used as a loading control 
for normalization of the signal. Results showed that HOXB13 is expressed in AR positive 
PCa cell lines, which have a luminal epithelial origin (LNCaP, vCaP, 22Rv1, MDA PCa 
2b), but also in PC-3 cells that are AR negative and small cell origin. RWPE-1, a normal 
immortalized prostate epithelial cell line expressing minuscule amounts of AR, does not 
express HOXB13. Similar results have been previously reported with some of the cell 
lines used in this study (Yao et al., 2019). 
MDA PCa 2b cell line has the highest expression level of HOXB13, but the standard 
deviation between the three biological replicates is very high as can be seen from the 
results (Figure 16). When these results were compared with Broad Institute RNASeq data, 
they were consistent, except that LNCaP had higher RPKM (Reads Per Kilobase Million) 
-value (155,5) than vCaP (136,8) whereas Western blot results indicated that LNCaP 
expressed less HOXB13. However, the standard deviation between the three biological 
replicates in Western blot results is quite high among all samples, and the loading is not 
evenly distributed as can be seen from the β-actin loading control. The loading pattern is 
however similar in all three replicates, which would suggest that there was probably 
something wrong with the protein concentration determination or the cell lines express -
actin quite differently. However, the results are normalized and the errors from loading 
differences should not affect the final results. 
Based on these results, it was determined that the LNCaP cell line express HOXB13 and 
they could be used in the further experiments and were transfected with the prime editing 
plasmids. 
 
5.2 Transfection and cell sorting affected LNCaP cell 
viability 
The cells were transfected with prime editing constructs, but they were mostly growing 
in clumps and not as a monolayer, and therefore many of them were discarded in the 




it functioned as a marker for identifying the transfected cells. The amount of the GFP-
positive cells obtained from the sorting for all four differently transfected cells (pegRNA-
PBS10, pegRNA-PBS13, pegRNA-PBS16 and negative control (PE only)) was very 
small and in addition to that, cells may have suffered from the transfection and from the 
sorting, and therefore they were growing very slowly and many of them died. Because of 
the small number of cells, the DNA concentration was very low, and the quality was not 
that good which affected the results obtained from ddPCR. 
5.3 PBS length is important for prime editing efficiency  
The fractional abundance of the G84E mutation compared to WT DNA was measured 
with ddPCR assay. DNA from LNCaP cells transfected with the pcDNA3-
HOXB13_G84E plasmid was used as a positive control for the assay to verify the 
performance and for identifying the expected cluster positions for thresholding. The 
concentration of the mutation in the sample was very high compared to the WT DNA 
which could be seen from the ddPCR data (Appendix Figure 2). NFW was used to ensure 
there were not any contamination, and negative control with WT DNA was used to 
monitor false positives.  
The assay was performed twice for the DNA from the prime edited cells. The first time 
the DNA amount was very low, especially for the PBS13 pegRNA (8 ng), and the amount 
of positive droplets in the assay was therefore very low and this caused high variation 
among the three wells containing the template (Figure 17A). The template amount was 
increased in the second assay (five-fold amount), and the efficiencies seemed to be even 
higher and with smaller standard deviations. However, the quality of the extracted DNA 
is not very good and the results from the assay do not seem to be that accurate when it 
comes to the PBS13 samples because the overall variation among samples was very high. 
Based on the results obtained from the second ddPCR assay, PCR was performed for the 
DNA extracted from cells transfected with pegRNA-PBS13 and a sample was sent for 
sequencing because if the efficiency would really be as high as the assay results indicated, 
the mutation would be more abundant. However, the WT DNA (G) was far more 
abundant than the mutation (A) and therefore, the efficiency of pegRNA with PBS13 
remains unclear, but based on the ddPCR and the sequencing results, it looks like it would 
be working. 
The average efficiency for PBS16 was 9,3 % in the first assay with small standard 




(average 11,1 %). Based on these results from both assays, it would seem like the 
pegRNA with PBS16 is working with 10 ,2 % efficiency.  
The pegRNA with PBS10 did not work at all based on the results. The reason presumably 
being that the PBS is too short for proper binding to the target DNA. 
These results show the importance of optimizing the PBS in the pegRNA since only a 
difference of three bases can lead to big differences in the editing efficiencies. The 
efficiency of PBS13 remains unknown, but the pegRNA with PBS16 can be used for 
further experiments.  
It is also important to consider that prime editing is such a novel method and has not yet 
been used that much, and therefore optimization is needed in different cell types. 
Anzalone et al. used HEK293 cells which are easily transfected and reached 30 – 60 % 
efficiencies. However, when using HeLa cells, the prime editing efficiency was 
approximately 10 % and similar to the efficiency observed in this study. Studies where 
prime editing was used in plants also reported quite low efficiencies (<10 %) at most 
target sites (Jiang et al., 2020; Lin et al., 2020), so the efficiency of pegRNA with PBS16 
used in here can be considered good.  













6. Conclusions and future perspectives 
The aim of the thesis was to generate tools for generating the G84E mutation in PCa cells 
with prime editing. For generating this mutation, the length of PBS of the pegRNA was 
optimized with three different constructs containing a PBS of 10, 13 or 16 nt, and their 
efficiencies were compared to one another. The pegRNA binds to the target strand where 
the mutation is introduced and therefore optimization is crucial for prime editing. Because 
the method is new and has not been used in many cell lines, it requires optimization of 
different components and editing conditions for achieving optimal efficiencies and for 
minimizing unwanted byproducts. Prime editing offers many possibilities but also 
challenges. They might not be capable of performing as large insertions and deletion as 
conventional CRISPR-Cas9 systems and because the edit is introduced with RT using 
RNA template, the stability of the RNA molecule might cause difficulties especially when 
it comes to long RNA molecules. Therefore, additional research is required. However, 
prime editing enables precise targeted editing with wider scope when compared to other 
gene editing tools and reduces the need for additional DNA templates and is not 
dependable on the HDR. 
The germline mutation G84E in HOXB13 was chosen for the experiments because it has 
been associated with increased PCa risk and it is a Finnish founder mutation (Ewing et 
al., 2012; Xu et al., 2013). Even though its association in PCa susceptibility has been 
known since its discovery by Ewing et al. in 2012, its role and mechanism in cancer 
progression remains elusive. The mutation is located within the MEIS interaction domain, 
but it has been demonstrated that the interaction does not interfere with the interaction 
between HOXB13 and MEIS1 in vitro (Johng et al., 2019). HOXB13 has both oncogenic 
and tumour suppressing functions but further studies are needed to understand its complex 
mechanisms in both normal prostate development and in tumorigenesis. It is known that 
the gene is required for normal prostate development (Economides et al. 2003) and that 
it interacts with AR (Norris et al., 2009), but how this mutation manifests itself is not 
known. It is possible that it affects protein stability since glycine, a small hydrophobic 
amino acid is replaced with glutamate which is hydrophilic. 
Cellular models of the G84E mutation in HOXB13 are needed to further study its role and 
mechanistic function in cancer progression, and that is why this thesis focused on this 
topic. The results showed that LNCaP, PC-3, vCaP, 22Rv1 and MDA PCa 2b cell lines 




not. LNCaP cells were chosen for prime editing of HOXB13 to introduce this mutation, 
and from three different pegRNA constructs, the ones with PBS of 16 and 13 nt worked, 
and the one with PBS of 10 nt did not, suggesting that it may be too short for proper 
binding to the target site. The efficiency of PBS13 remains unclear, but pegRNA with 
PBS16 worked with 10 % efficiency and it can be used for generating cellular model of 
the mutation. Further experiments would include isolation of the cellular clones and 
sequencing them, and ultimately using these models for functional experiments to 
elucidate the mechanism in which mutated HOXB13 promotes cancer progression. 
Checking the prime edited cells for unwanted byproducts would also be necessary for 
assessment of the off-target prime editing levels. 
Understanding the role of this mutation in cancer progression is important for developing 
treatments for patients carrying the germline mutation especially when targeted therapies 
are paving the way in drug development. Since PCa is a highly heritable disease and many 
variants are a result of single nucleotide variants (SNVs), effective tools for correcting 
these SNVs would be required. Prime editing offers a promising alternative for this, but 
currently much more research remains before they can be used in the treatment of genetic 
disorders.  
In summary, the results from this study implicate that prime editing can be efficiently 
used to introduce the G84E mutation into prostate cancer cells. Furthermore, the results 
show the importance of optimization the PBS length in the pegRNA and provides 














Appendix Figure 1 RNASeq data of HOXB13 expression in PCa cell lines. RNASeq data from 
Broad Institute Cancer cell line encyclopedia (https://portals.broadinstitute.org/ccle) was 
compared between five PCa cell lines and compared to protein expression levels of HOXB13. 





Appendix Figure 2 Droplet digital PCR (ddPCR) assay was performed to LNCaP cells 
transfected with pcDNA3-HOXB13_G84E plasmid. A= DNA droplets are clustered into four 
groups: FAM-(mut) and HEX-(WT) negative (black spots), FAM-positive (blue spots), HEX-
positive (green spots) and FAM- and HEX-positive (orange spots). B= Concentration results from 
ddPCR assay for positive control. Concentrations are plotted as copies per µl Three replicates 
per sample was used. Neg C= negative control, Pos C positive control diluted 1:100, NFW 
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